BeiGene Ltd - ADR
NASDAQ:BGNE 3:59:53 PM EDT
| Market Cap (Intraday) | 23.89B |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $241.61 |
| 50-Day MA | $288.14 |
| 200-Day MA | $324.76 |
BeiGene Ltd - ADR Stock, NASDAQ:BGNE
No. 30 Science Park Road, Zhong-Guan-Cun Life Science Park, Beijing, Beijing 102206
Cayman Islands
Phone: +86.10.85148500
Number of Employees: 5300
Description
BeiGene Ltd. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. It focuses on Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317), and Pamiparib (BGB-290). The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Beijing, China.